A protein-based vaccine for COVID-19 administered through the nose has shown promise in animal models, and developers are getting ready to conduct human trials.
A prototype biomarker that recognises antibiotic-induced gut dysbiosis has been created by a team from Ferring Pharmaceuticals, who believe the tool could help in developing future biotherapeutics.
A prototype biomarker that recognises antibiotic-induced gut dysbiosis has been created by a team from Ferring Pharmaceuticals, who believe the tool could help in developing future biotherapeutics.